2015 Form 10-K Summary
Filing identity and period: The provided filing is for PowerVerde, Inc., not 374Water Inc., and covers the fiscal year ended December 31, 2015. It is an annual report rather than a standalone fourth-quarter filing. The company later operated under a different corporate identity; investors should verify the issuer and ticker before relying on this filing.
Business Context
PowerVerde was a development-stage clean-energy company focused on waste-heat and solar thermal power-generation systems, including its Liberator system. Its natural-gas pipeline and wellhead project remained suspended. The company had not commenced planned principal operations and had generated no material product-sales revenue.
All reported revenue came from licensing and royalty arrangements related to legacy biotech intellectual property, not from the clean-energy business. The company had one full-time employee and relied on consultants for engineering and technical development.
Financial Performance and Position
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $529,861 | $428,747 |
| Research and development expense | $627,889 | $364,095 |
| General and administrative expense | $272,281 | $501,706 |
| Loss from operations | $(370,309) | $(437,054) |
| Net loss | $(426,634) | $(565,913) |
| Basic and diluted loss per share | $(0.01) | $(0.02) |
| Cash and cash equivalents at year-end | $5,601 | $4,736 |
| Cash used in operating activities | $(38,871) | $(337,480) |
| Working capital | $(288,544) | $78,580 |
| Accumulated deficit | $(11,659,311) | $(11,232,677) |
The filing reports no cost of goods sold and describes licensing revenue as the company’s sole material revenue source. The statement of operations lists gross profit of $529,681 for 2015, which does not mathematically reconcile to reported revenue of $529,861; this apparent $180 discrepancy should be verified against the filed financial statements.
Total assets were $302,682 at December 31, 2015, versus $327,822 in 2014. Total liabilities were $527,635 versus $516,141. Stockholders’ deficiency increased to $224,953 from $188,319.
Current liabilities included $412,115 of notes payable to related parties and $47,569 under a note for acquired intellectual property. The principal balance of the $400,000 related-party notes was due December 31, 2016, with interest payable at 10%. The company also reported $26,000 payable to related parties.
Material Changes Versus 2014
- Revenue increased 23.6%, from $428,747 to $529,861, entirely from biotech licensing fees.
- Research and development expense increased 72.5%, primarily due to stock-based compensation and continued Liberator development.
- General and administrative expense decreased 45.7%.
- Net loss improved by $139,279, although the company remained unprofitable.
- Operating cash burn declined substantially, but year-end cash remained extremely limited.
- Working capital deteriorated from a $78,580 surplus to a $288,544 deficit, primarily because related-party notes became current.
- The company recognized $390,000 of stock-based compensation in 2015, compared with none in 2014, including $208,000 related to repriced and extended management options and warrants and $180,000 related to new options.
- Outstanding warrants declined from 5,586,000 to 4,480,000, while outstanding options increased to 4,750,000.
Cash Flow, Liquidity, Outlook, and Risks
Management stated that year-end cash of $5,601 was sufficient to fund operations for approximately two months, through about May 2016. The company continued seeking private debt and equity financing and warned that failure to obtain substantial additional capital could force it to cease operations.
The independent auditor reported recurring losses, an accumulated deficit of $11.7 million, and substantial doubt about the company’s ability to continue as a going concern. The financial statements were prepared on a going-concern basis and contain no adjustments for a potential failure to continue operations.
Management expected 2016 biotech licensing revenue to exceed 2015 levels, but the filing provides no firm guidance or guarantee. The licensing agreement generating all company revenue was scheduled to terminate in March 2018 when the underlying patents expire.
Management planned to complete development and testing of the Liberator by mid-2016 and have a market-ready system by year-end 2016. The company targeted approximately 25,000 hours of continuous operation but acknowledged that technical issues might not be resolved and that the systems might never become commercially viable.
Key risks included dependence on a single legacy licensing revenue stream, insufficient liquidity, substantial financing needs, unproven technology, lack of product sales, competition from better-capitalized companies, dependence on key personnel, patent and intellectual-property uncertainty, reduced fossil-fuel prices, possible loss of government incentives, regulatory requirements, and potential dilution from future equity issuance.
A patent assigned to the company in June 2015 carried a 2% royalty obligation on related product or project revenues. The company’s principal legal proceeding had been settled in 2014, with all settlement payments made and the matter concluded.
Important Facts to Verify
- Confirm the issuer identity: the filing names PowerVerde, Inc., while the request identifies 374Water Inc.
- Reconcile the reported gross profit of $529,681 with revenue of $529,861 and zero cost of goods sold.
- Review the auditor’s going-concern qualification and the company’s stated approximately two-month cash runway.
- Confirm the terms, maturity, collateral, and related-party nature of the approximately $400,000 notes due December 31, 2016.
- Assess whether 2016 licensing revenue materialized and whether the revenue agreement remained sustainable before its March 2018 expiration.
- Verify technical testing results, durability claims, commercialization milestones, and any actual customer or product sales.
- Evaluate potential dilution from 4.75 million outstanding options and 4.48 million outstanding warrants.
- Review the reliance on an unsigned arrangement to use a related shareholder’s Scottsdale facility without rent.
- Consider the thinly traded OTCBB market, penny-stock restrictions, lack of dividends, and potential difficulty selling shares.